



*Off of time
& response
#48J.*

PATENT
Docket No. 286002020023

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231, on December 5, 2001.

U. Brava

Irina Brava

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Carol CLAYBERGER et al.

Serial No.: 08/653,294

Filing Date: May 24, 1996

For: IMMUNOMODULATING DIMERS

Examiner: M. DIBRINO

Group Art Unit: 1644

RECEIVED
DEC 20 2001
TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed November 1
2001, for which a response was due December 1, 2001. Accordingly, fee transmittal in duplicate
is enclosed.

Please enter the substitute Sequence Listing and remarks.

12/20/2001 AMONDAF1 00000042 031952 08653294

01 FC:115 110.00 CH

In the Sequence Listing:

Please replace the paper copy of the Sequence Listing filed on May 25, 2001 with the paper copy of the substitute Sequence Listing submitted herewith. A computer-readable copy (CRF copy) of the substitute Sequence Listing accompanies this response.

REMARKS

The Sequence Listing has been amended to be in compliance with Sequence Rules , 37 CFR 1.821 - 1.825.


The undersigned hereby states that the paper copy of the substitute Sequence Listing and computer readable form copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this sequence listing and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our Deposit Account No. 03-1952. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 5, 2001

By:


Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125



Application No.: 08653294

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.821(d) and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED

DEC 20 2001

TECH CENTER 180/2900

JUL 11 2001

TECH CENTER 1600/2900

SERIAL NUMBER: 08/653,294B

RECEIVED
DEC 20 2003
RESEARCH CENTER 1600 N. 16TH AVE
This may occur if your file
margin to .3; this will
es while spaces
les between numbers;
equence Reads. Please

- AMC – Biotechnology Systems Branch – 06/04/2001